Cambridge, Mass. — October 16, 2025 — Leads & Copy — Foghorn Therapeutics Inc. (Nasdaq: FHTX) has announced key development updates for its Selective ARID1B degrader program, which will be presented at the 8th Annual TPD and Induced Proximity Summit in Boston, MA, from October 27-30, 2025. Following the presentation, Foghorn will host a virtual investor event to review pipeline updates for its Selective ARID1B, Selective CBP, and Selective EP300 degrader programs.
Adrian Gottschalk, President and CEO of Foghorn, expressed enthusiasm about presenting progress on the Selective ARID1B degrader at the summit, highlighting its potential as a new class of drugs for endometrial, gastric, and bladder cancer patients. The investor event will cover the continued momentum for the Selective CBP and Selective EP300 degrader programs, which are advancing toward Investigational New Drug (IND) enabling studies.
The presentation, titled “Harnessing Degradation to Achieve Selectivity & First-in-Class Targeting of Challenging Chromatin Regulatory Proteins,” will be part of the Closing Keynote Plenary Session on Wednesday, October 29, at 3:45 p.m. EDT, presented by Steven Bellon, Chief Scientific Officer of Foghorn Therapeutics.
The virtual investor event, titled “Pipeline Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs,” will take place on Thursday, October 30, 2025, at 12 p.m. EDT. Registration is available via a provided link. The presentation will be available on the company’s website after the conference, with a live webcast and replay also accessible.
Foghorn Therapeutics is focused on discovering and developing medicines targeting genetically determined dependencies within the chromatin regulatory system. Their Gene Traffic Control® platform is used to identify and validate potential drug targets within this system, with multiple product candidates in oncology under development.
Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media), khellsvik@foghorntx.com
Source: Foghorn Therapeutics
